C4 Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CCCC research report →
About the company
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses.
- CEO
- Andrew J. Hirsch
- IPO
- 2020
- Employees
- 104
- HQ
- Watertown, MA, US
Price Chart
Get TickerSpark's AI analysis on CCCC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $296.52M
- P/E
- -3.01
- P/S
- 8.51
- P/B
- 1.93
- EV/EBITDA
- -2.93
- Div Yield
- 0.00%
- Gross Margin
- 94.83%
- Op Margin
- -326.56%
- Net Margin
- -297.76%
- ROE
- -50.68%
- ROIC
- -36.95%
- Revenue
- $35.95M · 1.02%
- Net Income
- $-104,994,000 · 0.31%
- EPS
- $-1.27 · 16.45%
- Op Income
- $-104,489,000
- FCF YoY
- -51.98%
- 52W High
- $5.17
- 52W Low
- $1.69
- 50D MA
- $3.84
- 200D MA
- $2.79
- Beta
- 2.91
- Avg Volume
- 3.19M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 10, 26 | REYNO LEONARD | other | 15,325 |
| Jul 10, 26 | REYNO LEONARD | other | 7,397 |
| Jul 1, 26 | Anderson Kenneth Carl | other | 2,650 |
| Jul 1, 26 | GROGAN DONNA ROY | other | 3,341 |
| Jun 24, 26 | Hughes Owen | other | 62,000 |
| Jun 24, 26 | Hoerter Steven L. | other | 62,000 |
| Jun 24, 26 | Koppikar Utpal | other | 62,000 |
| Jun 24, 26 | Anderson Kenneth Carl | other | 62,000 |
| Jun 24, 26 | Cooper Ronald Harold Wilfred | other | 62,000 |
| Jun 24, 26 | Bessen Laura | other | 62,000 |
Our CCCC coverage
Recent articles, reports, and earnings notes.
Want a deeper read on CCCC?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?
zacks.com · Jul 7
C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know
zacks.com · Jul 3
C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide Transcript
seekingalpha.com · Jun 18
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
zacks.com · Jun 18
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
globenewswire.com · Jun 11
C4 Therapeutics "Buy" On Cemsidomide Advancement And Competitor's Positive Readout
seekingalpha.com · Jun 2
C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com · Jun 1
C4 Therapeutics to Participate in Upcoming Conferences
globenewswire.com · May 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
Community Sentiment
Be the first to call it — is CCCC a buy or a sell from here?